134 related articles for article (PubMed ID: 19292886)
21. Cytohistopathologic hybrid renal cell carcinoma with papillary and clear cell features.
Mai KT; Kohler DM; Roustan Delatour NL; Veinot JP
Pathol Res Pract; 2006; 202(12):863-8. PubMed ID: 17034957
[TBL] [Abstract][Full Text] [Related]
22. Renal FNA-based typing of renal masses remains a useful adjunctive modality: evaluation of 31 renal masses with correlative histology.
Masoom S; Venkataraman G; Jensen J; Flanigan RC; Wojcik EM
Cytopathology; 2009 Feb; 20(1):50-5. PubMed ID: 18476991
[TBL] [Abstract][Full Text] [Related]
23. Differential expression of KAI1 metastasis suppressor protein in renal cell tumor histological subtypes.
Kauffman EC; Barocas DA; Chen YT; Yang XJ; Scherr DS; Tu JJ
J Urol; 2009 May; 181(5):2305-11. PubMed ID: 19303095
[TBL] [Abstract][Full Text] [Related]
24. Cytogenetic and molecular tumor profiling for type 1 and type 2 papillary renal cell carcinoma.
Klatte T; Pantuck AJ; Said JW; Seligson DB; Rao NP; LaRochelle JC; Shuch B; Zisman A; Kabbinavar FF; Belldegrun AS
Clin Cancer Res; 2009 Feb; 15(4):1162-9. PubMed ID: 19228721
[TBL] [Abstract][Full Text] [Related]
25. Prognostic factors in renal cell carcinoma.
Shuch BM; Lam JS; Belldegrun AS; Figlin RA
Semin Oncol; 2006 Oct; 33(5):563-75. PubMed ID: 17045085
[TBL] [Abstract][Full Text] [Related]
26. Ghrelin expression in normal kidney tissue and renal carcinomas.
Dagli AF; Aydin S; Karaoglu A; Akpolat N; Ozercan IH; Ozercan MR
Pathol Res Pract; 2009; 205(3):165-73. PubMed ID: 19054628
[TBL] [Abstract][Full Text] [Related]
27. Activated extracellular signal-regulated kinase is an independent prognostic factor in clinically confined renal cell carcinoma.
Campbell L; Nuttall R; Griffiths D; Gumbleton M
Cancer; 2009 Aug; 115(15):3457-67. PubMed ID: 19526593
[TBL] [Abstract][Full Text] [Related]
28. Quantitative proteomic analysis to discover potential diagnostic markers and therapeutic targets in human renal cell carcinoma.
Okamura N; Masuda T; Gotoh A; Shirakawa T; Terao S; Kaneko N; Suganuma K; Watanabe M; Matsubara T; Seto R; Matsumoto J; Kawakami M; Yamamori M; Nakamura T; Yagami T; Sakaeda T; Fujisawa M; Nishimura O; Okumura K
Proteomics; 2008 Aug; 8(15):3194-203. PubMed ID: 18615424
[TBL] [Abstract][Full Text] [Related]
29. Expression of two isozymes of acyl-coenzyme A: cholesterol acyltransferase-1 and -2 in clear cell type renal cell carcinoma.
Matsumoto K; Fujiwara Y; Nagai R; Yoshida M; Ueda S
Int J Urol; 2008 Feb; 15(2):166-70. PubMed ID: 18269457
[TBL] [Abstract][Full Text] [Related]
30. [Molecular and cytometric analysis of renal cell carcinoma cells. Concepts, techniques and prospects].
Li G; Lambert C; Gentil-Perret A; Genin C; Tostain J
Prog Urol; 2003 Feb; 13(1):1-13. PubMed ID: 12703348
[TBL] [Abstract][Full Text] [Related]
31. Immunohistochemical analysis for cytokeratin 7, KIT, and PAX2: value in the differential diagnosis of chromophobe cell carcinoma.
Memeo L; Jhang J; Assaad AM; McKiernan JM; Murty VV; Hibshoosh H; Tong GX; Mansukhani MM
Am J Clin Pathol; 2007 Feb; 127(2):225-9. PubMed ID: 17210525
[TBL] [Abstract][Full Text] [Related]
32. Diagnostic and prognostic molecular markers for renal cell carcinoma: a critical appraisal of the current state of research and clinical applicability.
Eichelberg C; Junker K; Ljungberg B; Moch H
Eur Urol; 2009 Apr; 55(4):851-63. PubMed ID: 19155123
[TBL] [Abstract][Full Text] [Related]
33. Application of SELDI-TOF-MS to identify serum biomarkers for renal cell carcinoma.
Xu G; Xiang CQ; Lu Y; Kang XN; Liao P; Ding Q; Zhang YF
Cancer Lett; 2009 Sep; 282(2):205-13. PubMed ID: 19362769
[TBL] [Abstract][Full Text] [Related]
34. Membrane trafficking of CD98 and its ligand galectin 3 in BeWo cells--implication for placental cell fusion.
Dalton P; Christian HC; Redman CW; Sargent IL; Boyd CA
FEBS J; 2007 Jun; 274(11):2715-27. PubMed ID: 17451431
[TBL] [Abstract][Full Text] [Related]
35. Immunohistochemical analysis of Reg IV in urogenital organs: Frequent expression of Reg IV in prostate cancer and potential utility as serum tumor marker.
Hayashi T; Matsubara A; Ohara S; Mita K; Hasegawa Y; Usui T; Arihiro K; Norimura S; Sentani K; Oue N; Yasui W
Oncol Rep; 2009 Jan; 21(1):95-100. PubMed ID: 19082448
[TBL] [Abstract][Full Text] [Related]
36. Onconeuronal antigen Cdr2 correlates with HIF prolyl-4-hydroxylase PHD1 and worse prognosis in renal cell carcinoma.
Kaufmann MR; Schraml P; Hermanns T; Wenger RH; Camenisch G
Exp Mol Pathol; 2013 Jun; 94(3):453-7. PubMed ID: 23531419
[TBL] [Abstract][Full Text] [Related]
37. Increased RANKL expression is related to tumour migration and metastasis of renal cell carcinomas.
Mikami S; Katsube K; Oya M; Ishida M; Kosaka T; Mizuno R; Mochizuki S; Ikeda T; Mukai M; Okada Y
J Pathol; 2009 Aug; 218(4):530-9. PubMed ID: 19455604
[TBL] [Abstract][Full Text] [Related]
38. [Renal cell carcinoma diagnosed at autopsy in Iceland 1971-2005].
Jonsson A; Hardarson S; Petursdottir V; Palsdottir HB; Jonsson E; Einarsson GV; Gudbjartsson T
Laeknabladid; 2008 Dec; 94(12):807-12. PubMed ID: 19182316
[TBL] [Abstract][Full Text] [Related]
39. Expression of prostate-specific membrane antigen in tumor-associated neovasculature of renal neoplasms.
Baccala A; Sercia L; Li J; Heston W; Zhou M
Urology; 2007 Aug; 70(2):385-90. PubMed ID: 17826525
[TBL] [Abstract][Full Text] [Related]
40. Renal cell carcinoma with rhabdoid features. Divergent differentiation of conventional (clear cell) carcinoma.
Klimis T; Karvounis H
J BUON; 2008; 13(3):433-6. PubMed ID: 18979563
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
